TROPHY - Candesartan Cilexetil Long-term Hypertension Prevention Trial
NCT ID: NCT00227318
Last Updated: 2011-08-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
1000 participants
INTERVENTIONAL
1998-07-31
2005-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Atacand Dose Ranging in Hypertensive Pediatric Subjects 1 Year to Less Than 6 Years of Age
NCT00244621
Evaluation of Atacand® (Candesartan) in Daily Medical Practice
NCT00837720
Atacand Dose Range Finding Study in Pediatric Subjects 6 to <17 Years of Age
NCT00244634
Efficacy, Safety, & Pharmacokinetics of Candesartan Cilexetil in Hypertensive Paediatric Subjects 6 to < 17 Years of Age
NCT00244595
Safety and Tolerability of MK-5478 in Participants With Hypertension (5478-001)
NCT01025843
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PREVENTION
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ATACAND
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* have an average clinic BP in the high normal range of \< 139/85-89 mmHg or 130-139/\< 89 mm Hg (high normal BP range) (mean systolic and/or diastolic pressure based on 3 consecutive measurements) derived from the average of clinic visits 1,2 and 3.
Exclusion Criteria
* have a stroke, myocardial infarction (MI), transient ischemic attack (TIA), the presence of any clinically significant evidence of atherosclerosis or hypertensive target organ involvement or any significant medical condition that may compromise participation in this study.
30 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Atacand Medical Science Director, MD
Role: STUDY_DIRECTOR
AstraZeneca
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Mobile, Alabama, United States
Research Site
Long Beach, California, United States
Research Site
Redondo Beach, California, United States
Research Site
Santa Ana, California, United States
Research Site
Tustin, California, United States
Research Site
Wilmington, Delaware, United States
Research Site
Washington D.C., District of Columbia, United States
Research Site
Bay Pines, Florida, United States
Research Site
Gainsville, Florida, United States
Research Site
Ocala, Florida, United States
Research Site
Chicago, Illinois, United States
Research Site
Shawnee Mission, Kansas, United States
Research Site
Chelsea, Michigan, United States
Research Site
Detroit, Michigan, United States
Research Site
Minneapolis, Minnesota, United States
Research Site
Jackson, Mississippi, United States
Research Site
Florissant, Missouri, United States
Research Site
Kansas City, Missouri, United States
Research Site
St Louis, Missouri, United States
Research Site
Buffalo, New York, United States
Research Site
Rochester, New York, United States
Research Site
Williamsville, New York, United States
Research Site
Asheville, North Carolina, United States
Research Site
Chapel Hill, North Carolina, United States
Research Site
Winston-Salem, North Carolina, United States
Research Site
Fargo, North Dakota, United States
Research Site
Canton, Ohio, United States
Research Site
Cleveland, Ohio, United States
Research Site
Columbus, Ohio, United States
Research Site
Oklahoma City, Oklahoma, United States
Research Site
Allentown, Pennsylvania, United States
Research Site
Fleetwood, Pennsylvania, United States
Research Site
Pittsburgh, Pennsylvania, United States
Research Site
Providence, Rhode Island, United States
Research Site
Warwick, Rhode Island, United States
Research Site
Charleston, South Carolina, United States
Research Site
Memphis, Tennessee, United States
Research Site
Dallas, Texas, United States
Research Site
Houston, Texas, United States
Research Site
Richmond, Virginia, United States
Research Site
Morgantown, West Virginia, United States
Research Site
Milwaukee, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Julius S, Nesbitt SD, Egan BM, Weber MA, Michelson EL, Kaciroti N, Black HR, Grimm RH Jr, Messerli FH, Oparil S, Schork MA; Trial of Preventing Hypertension (TROPHY) Study Investigators. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med. 2006 Apr 20;354(16):1685-97. doi: 10.1056/NEJMoa060838. Epub 2006 Mar 14.
Kang S, Little RJ, Kaciroti N. Missing not at random models for masked clinical trials with dropouts. Clin Trials. 2015 Apr;12(2):139-48. doi: 10.1177/1740774514566662. Epub 2015 Jan 27.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D2455L00010
Identifier Type: OTHER
Identifier Source: secondary_id
SH-AHM-0030
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.